Welcome to our dedicated page for Travere Therapeutics news (Ticker: $TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Travere Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Travere Therapeutics's position in the market.
Travere Therapeutics, Inc. (Nasdaq: TVTX) will present data on FILSPARI (sparsentan) at the National Kidney Foundation (NKF) Spring Clinical Meetings and the European Renal Association (ERA) Congress. The presentations showcase FILSPARI's efficacy over traditional treatments, highlighting its benefits in patients with IgA nephropathy.
Travere Therapeutics, Inc. (NASDAQ: TVTX) will be participating in upcoming investor conferences including the BofA Securities Health Care Conference on May 15, 2024, and the Jefferies Global Healthcare Conference on June 5, 2024. The live webcasts of the presentations can be accessed on Travere's website with replays available for 30 days after each event.
Travere Therapeutics reported strong financial results for the first quarter of 2024, showcasing significant growth and achievements in key regulatory milestones. The FDA granted Priority Review for converting FILSPARI to full approval for IgAN in the U.S., with a PDUFA target action date of September 5, 2024. European Commission granted conditional marketing authorization for FILSPARI in Europe. The Company dosed the first patients in the pivotal Phase 3 HARMONY Study and has cash, cash equivalents, and marketable securities totaling $441.0 million as of March 31, 2024.
Travere Therapeutics, Inc. (NASDAQ: TVTX) will report its first quarter 2024 financial results on May 6, 2024. The company will host a conference call and webcast to discuss the results and provide a business update. Details can be accessed on Travere's Investor page.